In conclusion, preliminary data on COVID-19 indicate a substantial risk that infusions of TF/CD142-expressing MSC products could aggravate the pro-thrombotic state of COVID-19 (and other categories of patients in a hypercoagulable state) and increase the risk of associated complications such as DIC, thrombosis, and thrombotic multi-organ failure (7, 19, 20, 59). This evidence concerns the gene TF and COVID-19.